Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
Masumi Ueda, Tammy Stefan, Lindsay Stetson, James J Ignatz-Hoover, Benjamin Tomlinson, Richard J Creger, Brenda Cooper, Hillard M Lazarus, Marcos de Lima, David N Wald, Paolo F Caimi, Masumi Ueda, Tammy Stefan, Lindsay Stetson, James J Ignatz-Hoover, Benjamin Tomlinson, Richard J Creger, Brenda Cooper, Hillard M Lazarus, Marcos de Lima, David N Wald, Paolo F Caimi
Abstract
Glycogen synthase kinase-3 (GSK3) inhibitors induce differentiation and growth inhibition of acute myeloid leukemia (AML) cells. Our pre-clinical studies showed GSK3 inhibition leads to sensitization of AML cells to tretinoin-mediated differentiation. We conducted a phase I trial of lithium, a GSK3 inhibitor, plus tretinoin for relapsed, refractory non-promyelocytic AML. Nine patients with median (range) age 65 (42-82) years were enrolled. All subjects had relapsed leukemia after prior therapy, with a median (range) of 3 (1-3) prior therapies. Oral lithium carbonate 300 mg was given 2-3 times daily and adjusted to meet target serum concentration (0.6 to 1.0 mmol/L); tretinoin 22.5 or 45 mg/m2/day (two equally divided doses) was administered orally on days 1-7 and 15-21 of a 28-day cycle. Four patients attained disease stability with no increase in circulating blasts for ≥4 weeks. Median (range) survival was 106 days (60-502). Target serum lithium concentration was achieved in all patients and correlated with GSK3 inhibition in leukemic cells. Immunophenotypic changes associated with myeloid differentiation were observed in five patients. The combination treatment led to a reduction in the CD34+ CD38- AML stem cell population both in vivo and in vitro. The combination of lithium and tretinoin is well-tolerated, induces differentiation of leukemic cells, and may target AML stem cells, but has limited clinical activity in the absence of other antileukemic agents. The results of this clinical trial suggest GSK3 inhibition can result in AML cell differentiation and may be a novel therapeutic strategy in this disease, particularly in combination with other antileukemic agents. Lithium is a weak GSK3 inhibitor and future strategies in AML treatment will probably require more potent agents targeting this pathway or combinations with other antileukemic agents. This trial is registered at ClinicalTrials.gov NCT01820624.
Keywords: AML; differentiation; lithium; stem cells; tretinoin.
Copyright © 2020 Ueda, Stefan, Stetson, Ignatz-Hoover, Tomlinson, Creger, Cooper, Lazarus, de Lima, Wald and Caimi.
Figures
References
- Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. . Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. (2013) 369:111–21. 10.1056/NEJMoa1300874
- Gupta K, Gulen F, Sun L, Aguilera R, Chakrabarti A, Kiselar J, et al. . GSK3 is a regulator of RAR-mediated differentiation. Leukemia. (2012) 26:1277–85. 10.1038/leu.2012.2
- Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, et al. . The intersection of genetic and chemical genomic screens identifies GSK-3alpha as a target in human acute myeloid leukemia. J Clin Investig. (2012) 122:935–47. 10.1172/JCI46465
- Si J, Mueller L, Collins SJ. GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells. Leukemia. (2011) 25:1914–8. 10.1038/leu.2011.171
- Song EY, Palladinetti P, Klamer G, Ko KH, Lindeman R, O'Brien TA, et al. . Glycogen synthase kinase−3beta inhibitors suppress leukemia cell growth. Exp Hematol. (2010) 38:908–21.e1. 10.1016/j.exphem.2010.06.001
- Holmes T, O'Brien TA, Knight R, Lindeman R, Shen S, Song E, et al. . Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells. (2008) 26:1288–97. 10.1634/stemcells.2007-0600
- Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. (2008) 455:1205–9. 10.1038/nature07284
- Gupta K, Stefan T, Ignatz-Hoover J, Moreton S, Parizher G, Saunthararajah Y, et al. . GSK-3 inhibition sensitizes acute myeloid leukemia cells to 1,25D-mediated differentiation. Cancer Res. (2016) 76:2743–53. 10.1158/0008-5472.CAN-15-2290
- Hu S, Ueda M, Stetson L, Ignatz-Hoover J, Moreton S, Chakrabarti A, et al. . A novel glycogen synthase kinase-3 inhibitor optimized for acute myeloid leukemia differentiation activity. Mol Cancer Ther. (2016) 15:1485–94. 10.1158/1535-7163.MCT-15-0566
- Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. (1996) 93:8455–9. 10.1073/pnas.93.16.8455
- O'Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. (2009) 37:1133–8. 10.1042/BST0371133
- Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem. (2003) 278:33067–77. 10.1074/jbc.M212635200
- Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. (2009) 101:708–20. 10.1093/jnci/djp079
- Rogers JE, Yang D. Differentiation syndrome in patients with acute promyelocytic leukemia. J Oncol Pharm Pract. (2012) 18:109–14. 10.1177/1078155211399163
- Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol. (1999) 10:666–74.
- Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, et al. . Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. (2007) 110:3547–51. 10.1182/blood-2007-06-095844
- Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. (2010) 115:453–74. 10.1182/blood-2009-07-235358
- Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. . Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. (2003) 21:4642–9. 10.1200/JCO.2003.04.036
- Pahl HL, Scheibe RJ, Zhang DE, Chen HM, Galson DL, Maki RA, et al. . The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem. (1993) 268:5014–20.
- Martin TR, Mongovin SM, Tobias PS, Mathison JC, Moriarty AM, Leturcq DJ, et al. . The CD14 differentiation antigen mediates the development of endotoxin responsiveness during differentiation of mononuclear phagocytes. J Leukoc Biol. (1994) 56:1–9. 10.1002/jlb.56.1.1
- Tao W, Wang M, Voss ED, Cocklin RR, Smith JA, Cooper SH, et al. . Comparative proteomic analysis of human CD34+ stem/progenitor cells and mature CD15+ myeloid cells. Stem Cells. (2004) 22:1003–14. 10.1634/stemcells.22-6-1003
- Gadhoum SZ, Sackstein R. CD15 expression in human myeloid cell differentiation is regulated by sialidase activity. Nat Chem Biol. (2008) 4:751–7. 10.1038/nchembio.116
- Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al. . Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. (2000) 7:793–803. 10.1016/S1074-5521(00)00025-9
- Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. (2001) 280:720–5. 10.1006/bbrc.2000.4169
- Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. . Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. (2011) 17:1086–93. 10.1038/nm.2415
- Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. . Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. (2014) 506:328–33. 10.1038/nature13038
- Cui W, Zhang D, Cunningham MT, Tilzer L. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings. Int J Lab Hematol. (2014) 36:636–49. 10.1111/ijlh.12193
- Baer MR, Stewart CC, Dodge RK, Leget G, Sule N, Mrozek K, et al. . High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. (2001) 97:3574–80. 10.1182/blood.V97.11.3574
- Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, et al. . An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. (2016) 57:1800–6 10.3109/10428194.2015.1122781
- Gray JE, Infante JR, Brail LH, Simon GR, Cooksey JF, Jones SF, et al. . A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Invest New Drugs. (2015) 33:1187–96. 10.1007/s10637-015-0278-7
- Brail LH, Gray JE, Burris H, Simon GR, Cooksey J, Jones SF, et al. A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. J Clin Oncol. (2011) 29:3030 10.1200/jco.2011.29.15_suppl.3030
- del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, et al. . Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimer's Dis. (2013) 33:205–15. 10.3233/JAD-2012-120805
- Tolosa E, Litvan I, Hoglinger GU, Burn D, Lees A, Andres MV, et al. . A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. (2014) 29:470–8. 10.1002/mds.25824
- Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, et al. . Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metab Dispos. (2013) 41:714–26. 10.1124/dmd.112.048488
Source: PubMed